Press Release

November 19, 2018

Generation Bio to Present at the Evercore ISI Healthcare Conference

CAMBRIDGE, Mass., November 19, 2018 —  Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, today announced that the company will present at the Evercore ISI Healthcare Conference in Boston, MA. President and Chief Executive Officer Geoff McDonough will provide an overview of the company on Wednesday, November 28, 2018 at 9:50 a.m. EST.

To access a live webcast and subsequent archived recording of the presentation, please visit the “News” section on the Generation Bio website at

About Generation Bio

Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease. The company’s therapies are based on its proprietary ceDNA technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime. Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit or follow @generationbio.


Investor contact:
Stern Investor Relations
(212) 362-1200

Media contact:
Sarah Sutton
Ten Bridge Communications
(518) 932-3680

Take a seat at the table.

We are always looking for those who are ready to share their vision, talent, and tenacity—who believe in our mission and themselves.

Imagine a world without genetic disease.

What do you see? More health? Fewer doctor appointments? More bike riding? More peanut butter and jelly sandwiches? More life?
See our shared vision.